MedTrace Logo

Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease

NCT00693004 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2009-07-30

No results posted yet for this study

Summary

A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 monotherapy in subjects with Alzheimer's disease. The study consists of a 3-month double-blind treatment period and an optional 3-month extension period.

Conditions

Interventions

DRUG

PRX-03140

DRUG

Donepezil

DRUG

Placebo

Sponsors & Collaborators

  • Epix Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693004 on ClinicalTrials.gov